OR WAIT null SECS
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science, according to the press release.
BioPharmics developed a series of industry-leading algorithms and software for 3D ligand-based and structure based computational drug design, including software for 2D to 3D ligand conversion and conformer generation, molecular docking, molecular similarity, and binding affinity prediction. Additionally, these highly performant products have all been analyzed and their results demonstrated in numerous peer-reviewed papers, specifically published jointly with key pharmaceutical industry partners, according to the release.
“After years of close collaboration, we are delighted that Optibrium was chosen to support BioPharmics’ continued scientific innovation and expanding customer base,” said Dr Matthew Segall, CEO, Optibrium in a press release. “We are delighted to welcome Ajay and Ann to the team. Their extensive experience in computational chemistry and biology, alongside BioPharmics’ world-leading software for 3D ligand- and structure-based design, will bring Optibrium to the forefront of these essential technologies for small molecule discovery and design.”
Dr Ajay Jain, founder and CEO of BioPharmics, added that their team believes that there is no better team to continue the powerful software developments that BioPharmics has introduced over the years. “I look forward to working as part of the Optibrium team to expand their internal expertise in 3D drug design, as well as on future drug discovery innovations,” he said in a press release.